These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Canto MI; Harinck F; Hruban RH; Offerhaus GJ; Poley JW; Kamel I; Nio Y; Schulick RS; Bassi C; Kluijt I; Levy MJ; Chak A; Fockens P; Goggins M; Bruno M; Gut; 2013 Mar; 62(3):339-47. PubMed ID: 23135763 [TBL] [Abstract][Full Text] [Related]
23. Surveillance of Individuals with a Family History of Pancreatic Cancer and Inherited Cancer Syndromes: A Strategy for Detecting Early Pancreatic Cancers. Matsubayashi H; Kiyozumi Y; Ishiwatari H; Uesaka K; Kikuyama M; Ono H Diagnostics (Basel); 2019 Oct; 9(4):. PubMed ID: 31683730 [TBL] [Abstract][Full Text] [Related]
24. Screening of Patients at Risk for Familial Pancreatic Cancer: What Is Beneficial? Torphy RJ; Schulick RD Surg Clin North Am; 2018 Feb; 98(1):25-35. PubMed ID: 29191275 [TBL] [Abstract][Full Text] [Related]
25. Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations. Lal G; Liu G; Schmocker B; Kaurah P; Ozcelik H; Narod SA; Redston M; Gallinger S Cancer Res; 2000 Jan; 60(2):409-16. PubMed ID: 10667595 [TBL] [Abstract][Full Text] [Related]
26. BRCA1 and pancreatic cancer: pedigree findings and their causal relationships. Lynch HT; Deters CA; Snyder CL; Lynch JF; Villeneuve P; Silberstein J; Martin H; Narod SA; Brand RE Cancer Genet Cytogenet; 2005 Apr; 158(2):119-25. PubMed ID: 15796958 [TBL] [Abstract][Full Text] [Related]
27. Identification of Cystic Lesions by Secondary Screening of Familial Pancreatic Cancer (FPC) Kindreds Is Not Associated with the Stratified Risk of Cancer. Sheel ARG; Harrison S; Sarantitis I; Nicholson JA; Hanna T; Grocock C; Raraty M; Ramesh J; Farooq A; Costello E; Jackson R; Chapman M; Smith A; Carter R; Mckay C; Hamady Z; Aithal GP; Mountford R; Ghaneh P; Hammel P; Lerch MM; Halloran C; Pereira SP; Greenhalf W Am J Gastroenterol; 2019 Jan; 114(1):155-164. PubMed ID: 30353057 [TBL] [Abstract][Full Text] [Related]
33. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589 [TBL] [Abstract][Full Text] [Related]
34. Importance of age of onset in pancreatic cancer kindreds. Brune KA; Lau B; Palmisano E; Canto M; Goggins MG; Hruban RH; Klein AP J Natl Cancer Inst; 2010 Jan; 102(2):119-26. PubMed ID: 20068195 [TBL] [Abstract][Full Text] [Related]
36. A histomorphologic comparison of familial and sporadic pancreatic cancers. Singhi AD; Ishida H; Ali SZ; Goggins M; Canto M; Wolfgang C; Meriden Z; Roberts N; Klein AP; Hruban RH Pancreatology; 2015; 15(4):387-391. PubMed ID: 25959245 [TBL] [Abstract][Full Text] [Related]
37. Prevalence of BRCA2 and CDKN2a mutations in German familial pancreatic cancer families. Slater EP; Langer P; Fendrich V; Habbe N; Chaloupka B; Matthäi E; Sina M; Hahn SA; Bartsch DK Fam Cancer; 2010 Sep; 9(3):335-43. PubMed ID: 20195775 [TBL] [Abstract][Full Text] [Related]
38. Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Langer P; Kann PH; Fendrich V; Habbe N; Schneider M; Sina M; Slater EP; Heverhagen JT; Gress TM; Rothmund M; Bartsch DK Gut; 2009 Oct; 58(10):1410-8. PubMed ID: 19470496 [TBL] [Abstract][Full Text] [Related]